Prime Minister Manuel Valls, who vows to slash spending and lower taxes on business, could either sink or replace French President Hollande
Fiat Chrysler's police vehicle is a muscle car with cool features and the rear-wheel drive that many cops prefer
Its purchases alarm some right-wing conspiracy theorists, but in fact its ammo buying has been declining for years
Apple's iPhone sales last quarter exceed estimates, while iPad sales disappoint
Its revenue keeps rising, and it keeps adding more customers
Apple's new campus, designed by Stephen Behling and Sir Norman Foster, is raising some eyebrows
Amazon will be the first Internet-TV provider to stream HBO shows—if not new ones—by offering them on Instant Video and its Fire TV device
Expatriate professionals prepare for change when they set off to work abroad, but the real shock awaits their return to the corporation
Startup Casper bets it can sell foam-only bedding via a Web-only, direct-to-consumer business model
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."